ACIU
ACIU
NASDAQ · Biotechnology

Ac Immune Sa

$2.49
-0.01 (-0.40%)
Financial Highlights (FY 2026)
Revenue
3.63M
Net Income
-71,457,824
Gross Margin
Profit Margin
-1,971.7%
Rev Growth
-2.9%
D/E Ratio
0.10
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 67.7% 67.7%
Operating Margin -1,940.0% -1,746.0% 0.2% 0.2%
Profit Margin -1,971.7% -1,873.1% 0.2% 0.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 3.63M 3.74M 119.79M 119.57M
Gross Profit 81.15M 81.00M
Operating Income -70,386,527 -65,226,394 217.2K 194.6K
Net Income -71,457,824 -66,219,153 199.8K 200.3K
Gross Margin 67.7% 67.7%
Operating Margin -1,940.0% -1,746.0% 0.2% 0.2%
Profit Margin -1,971.7% -1,873.1% 0.2% 0.2%
Rev Growth -2.9% -2.9% -0.9% +8.9%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 11.22M 11.22M 114.17M 132.63M
Total Equity 110.90M 110.90M 166.00M 182.25M
D/E Ratio 0.10 0.10 0.69 0.73
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -67,778,645 -66,299,127 316.5K 305.4K
Free Cash Flow 248.3K 178.6K